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The margin index was 21% in 2009 and 20% in 2010. Since all drugs were Rx 
(margin was set up to 12%, VAT was fixed to 8%), this was completely expected. At 
the end of 2010, two medicines: levonorgestrel (1,5mg) and orlistat (60mg), were 
authorised as OTC medicines (free pricing, margin:25%, VAT:18%). ConClusions: 
“Lifestyle-medicines” are difficult to define. Market success depends on prod-
uct characteristics, effectiveness, tolerability, convenient drug-delivery format, 
simple dosing regimen, good safety profile, first-to-market position, premium 
prices, sustained media attention, Rx-OTC switch potential and reimbursement 
potential. Although more new “lifestyle-medicines” will be authorised in Serbia, 
market share is expected to decrease because of low purchasing power and low 
reimbursement potential.
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Is ExtErnal PrIcE rEfErEncIng an aPProPrIatE Drug PolIcy from an 
EffIcIEncy, EquIty, anD qualIty PErsPEctIvE?
Wouters O.J., Kanavos P.
London School of Economics and Political Science, London, UK
objeCtives: Different external price referencing (EPR) configurations are applied 
by countries worldwide. Depending on how EPR schemes are implemented, 
they may have varying effects on short- and long-run prices, market dynam-
ics, key stakeholders, and other relevant endpoints. This research evaluated 
the merits and demerits of EPR from an efficiency, equity, and quality perspec-
tive. Methods: A theoretical and empirical analysis of the effectiveness of 
EPR was conducted, based on a systematic review of the literature and stake-
holder interviews. As EPR has been most common in Europe, the study focused 
on this region. Results: The systematic review identified 100 relevant articles. 
The articles were categorised according to study characteristics and four major 
themes were identified; these findings were confirmed by the interviewees. The 
evidence suggests that EPR schemes often generate disproportionate price lev-
els in relation to national abilities to pay; this is likely due to the reliance on 
foreign list prices which do not reflect negotiated discounts. If manufacturers 
apply launch strategies to exert upward pressure on prices (e.g. launch delays or 
product withdrawals), it may also limit patient access to life-saving medicines. 
In addition, the bureaucratic complexity of many EPR schemes may undermine 
the objectives of EPR use (i.e. cost containment and macroeconomic efficiency). 
Finally, widespread EPR application may stifle pharmaceutical and biomedical 
innovation. ConClusions: A national pricing policy should provide an effec-
tive, predictable, transparent, and stable pricing environment for pharmaceutical 
products. It should internalise national priorities for health and industrial policy, 
including cost containment, employment, innovation, and trade promotion. EPR 
is associated with important short- and long-term issues. If EPR is going to con-
tinue to be applied by EU Member States and other countries, then it is necessary 
to establish guiding principles to govern EPR use across jurisdictions. Still, dif-
ferential pricing and risk-sharing agreements may represent more sustainable 
policy options.
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DoEs EuroPE rEwarD rEformulatIons? a Data DrIvEn analysIs of 
valuE PrEsErvatIon tHrougH rEformulatIon
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objeCtives: Reformulating existing drugs can improve patient convenience, com-
pliance and create new uses for the product. However, reformulations cost millions 
of Euros - a risky investment without guaranteed exclusivity or returns. This study 
assessed whether markets reward incremental value creation through reformu-
lation by comparing sales performance close to patent expiry for reformulated 
and non-reformulated products. Methods: IMS MIDAS data was interrogated to 
identify 829 small molecule, non-generic products which had peak sales above € 5M 
and lost patent protection between 2001 and 2010 in EU-5 (France, Germany, Italy, 
Spain and UK). Ex-manufacturer sales value (€ ) 2 years after patent expiry was 
compared with sales value 4 years earlier to calculate percentage value erosion 
for each of the 829 products. A subset of 133 products which launched at least 1 
reformulation close to patent protection expiry (launch between 3 years before 
and 1 year after patent protection expiry) were analysed to assess whether value 
erosion varied across countries or therapy areas. Results: Mean ex-manufacturer 
sales value erosion of reformulated products (24%) was significantly less than 
non-reformulated products (37%, P< 0.01). Reformulated product value erosion 
varied with country and therapy area. Germany saw highest number of reformu-
lations launched yet only reformulations launched in Italy showed significantly 
less value erosion than non-reformulated products (P< 0.01). Across therapy areas, 
reformulations were most common in nervous system, metabolism and anti-
infective categories. However, reformulated anti-infective product value erosion 
was pronounced while musculoskeletal and nervous system products experi-
enced significantly less value erosion than for non-reformulated products (both 
P< 0.05). ConClusions: Overall, reformulated products do maintain more value 
than non-reformulated products following loss of patent protection. Chronic 
disorders e.g. nervous and musculoskeletal system disorders appear to be the 
most promising areas for reformulating. Future reformulation potential is tightly 
linked to country-specific pricing and market access policy decisions to recognise 
incremental value products.
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comParIson of PHarmacEutIcal PrIcEs In 56 countrIEs
Davey P.
Macquarie University, Sydney, Australia
objeCtives: To construct a number of pharmaceutical price indices for a broad set 
of countries, covering a range of regions, including countries with different levels 
objeCtives: Competition within therapeutic drug classes from “follow-on” drugs 
has been a highly controversial issue. Manufacturers launching new molecules 
in existing drug classes have often been criticized for inflating health systems’ 
expenses, but it has been argued that such drugs increase therapeutic options. 
Economic theory suggests that follow-on drugs induce price competition. We con-
tribute to this discussion by addressing the topic of pricing at market entry and 
price development in the German market with the distinct focus on competition 
within already existing drug classes. Methods: We measure determinants of 
price strategies of follow-on drugs using regression analyses, considering all new 
molecules launched in the German market in the period from 1993-2008. Prices of 
products are standardized on Defined Daily Dosages controlling for sales volumes 
based on data from the IMS Health DPM database, a census audit of pharmaceutical 
sales in Germany, and for the therapeutic quality of a new product using ratings 
by Fricke/Klaus as a proxy for innovation. Results: We identify prices correlating 
with therapeutic value at market entry. While the first two molecules engage in 
quality competition by offering more therapeutic options, price discounts below the 
market price can be observed from the third entrant on. Price discounts are even 
more distinct in development races with several drugs entering the market within 
two years and in classes with a low degree of therapeutic differentiation. Prices 
remain relatively constant over time. ConClusions: This study contributes to 
assessments of competition in pharmaceutical markets focusing on price strategies 
of new market entrants. After an initial phase of market building, further follow-on 
products induce price competition. Largely unchanged prices after 4 years may be 
interpreted as quality competition and can be attributed to prices in Germany being 
anchor point for international price referencing.
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objeCtives: Although generic drugs are considered to be therapeutically equivalent 
to their off-patent (branded) counterparts, the overall impact of generic substitu-
tion on clinical and economic outcomes has not been comprehensively evaluated. 
The goal of this study was to test whether 1) generics and branded products yield 
the same health outcomes; and 2) generic therapies save economic resources ver-
sus branded therapies for de-novo patients and patients on maintenance ther-
apy. Methods: We performed a systematic literature review in Medline, Cochrane 
Database of Systematic Reviews and Embase (2000-2012) to identify original research 
studies on clinical or economic outcomes with either independent or pre-post com-
parator groups. Data were aggregated using a standardized extraction form. For 
each included study, outcomes were categorized as favoring or opposing generic 
drug substitution. As we compared different outcomes, one publication could 
contribute to multiple outcome comparisons. Results: We included 40 studies 
that led to 121 outcome comparisons. Similar clinical effects were found in 74% 
of all studies in which patients were initiating therapy (de novo) and 64% of all 
studies involving maintenance therapy comparisons. 100% of the economic analy-
ses of de novo patients and 56% of comparisons of maintenance therapy patients 
showed lower costs associated with the use of original brand. Overall, 66% of the 
outcome comparisons reported similar clinical outcomes and 64% suggested that 
brand products lower costs compared to generic substitution. ConClusions: Our 
analyses suggested that clinical effects were mainly similar, whereas economic 
savings of brand to generic drug substitution may be overstated, particularly in 
sensitive therapeutic areas such as anti-epileptic drugs or immunosuppressives. 
More systematic research comparing clinical and cost outcomes with or without 
generic substitution is needed to inform policy on the use of generic substitu-
tion. ACKnoWledGeMents: We would like to thank Anke-Peggy Holtorf and 
Zoltán Kaló for their scientific input.
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1Pharmacoeconomics Section of the Pharmaceutical Association of Serbia, Belgrade, Serbia and 
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objeCtives: To determine whether there was a difference between wholesale 
prices, utilization and market share, as well as to explain Rx-OTC switches and 
reimbursement possibilities of “lifestyle-medicines”, in 2009 and 2010, before and 
after the adoption of new Medicines Law, in Serbia. Methods: We investigated 
how many potential “lifestyle-medicines”, satisfying the previously determined 
criteria, were authorised for sale. Utilization, price changes and reimbursement 
status were monitored. Price index and margin index were calculated using the 
formula: I= QxP (index(I),quantity(Q),price(P)). To compare the differences in prices 
and utilization, non-parametric Mann-Whitney test was used. To test difference 
in market shares, T-test of proportion was used. Results: There were 21 regis-
tered “lifestyle-medicines”. Five medicines (oral contraceptives) were listed. In 
2009, there were 1,763,030 units dispensed worth 16,074,922€ . In 2010, 1,814,405 
units were dispensed while total value was 14,129,792€ . The average sales(€ ) were 
higher in 2009, which is not in line with the expected growth trend, but observed 
difference was not statistically significant. The wholesale price-index 2009/2010 
was -13%. This means that prices were 13% lower in 2010. In fact, during 2010, 
prices remained the same in national currency, which weakened against euro. 
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IntroDuctIon of InnovatIons Into tHE gErman statutatory 
rEImbrusmEnt systEm – factors for succEss
Krensel M.
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
objeCtives: Innovations are fundamental for progress and improvement in health 
care and medicine. In German hospitals provision of all kind of services is allowed, 
since it is not forbidden explicitly. But it is paid only if it is represented in the reim-
bursement system. For integration of innovations into this system applications must 
be addressed by each hospital which wants to provide a special innovative service in 
each year separately to the German institute for reimbursement in hospitals which 
decides about (additional) payments. The objective is to determine which factors 
influence the chance for innovations being incorporated. Results can be used by hos-
pitals to assess if certain innovations have good chances to be afforded. Methods: 
Data about applications, their approval and assessment, number of hospitals and 
years in which approvals were made were obtained from the German institute for 
reimbursement systems in hospitals from 2005 to 2011. Innovations have been 
classified into types of methods. Applications made by medical associations and 
for orphan drugs were identified. Associations between each variable and success 
of application were calculated. In all analyses Bonferroni correction was conducted. 
Finally intercorrelation of variables was assessed. Results: Chance of integration 
was best for innovations with the following characteristics: Applications were made 
by medical associations, innovations were applied over a period of 6 years and by 
more than 100 hospitals, subjects were drugs (especially orphan drugs) and they 
belong to gynecology, oncology or cardiology and vascular medicine. Intercorrelation 
between these independent variables is also a predictor of success in some constel-
lations. ConClusions: The success of integration of a new method depends on all 
analyzed variables. Therefor all of them have to be taken into account when decision 
is made about what innovation should be applied.
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Heeg B.1, Schoeman O.2, Mueller S.3, Wilke T.3
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objeCtives: There are three main governmental stakeholders in the German 
AMNOG process: The IQWiG assesses the AMNOG drug manufacturer’s submission 
and provides advice on any additional benefit to the GBA who makes the final deci-
sion. Following confirmation of additional benefit, manufacturers start price nego-
tiations with the GKV-Spitzenverband (association of German sickness funds). The 
aim of this research is to assess the AMNOG-decisions so far. Methods: All AMNOG 
decisions up to December 2012 were analyzed in terms of additional benefit deci-
sion, reason for additional benefit decision, reimbursed price versus manufacturer 
set price, and consistency in IQWiG-recommendation and GBA-decision. Results: 
In total AMNOG decisions of 41 drugs (60 subgroups) were identified. IQWiG rec-
ommendations were as follows: 22 cases demonstrated no additional benefit, 2 
unquantifiable benefit, 3 slight benefit, 7 significant benefit, and 7 additional benefit 
due to orphan-drug status. In 6 cases, the GBA upgraded IQWIG’s recommenda-
tions. In 3 cases it downgraded it. The following reasons were identified for GBA 
“additional benefit decisions” (multiple reasons apply for some decisions): No or 
non-quantifiable additional benefit (18 cases); no reliable clinical data (14 cases; 3 
cases no submission), wrong comparator (5 cases); additional benefit in any form 
(23 cases): mortality advantages (7 cases), orphan drug status (7 cases), morbidity 
advantages (8 cases), and QoL advantages (3 cases). The negotiated price rebates 
varied from 4.7% to 70.7% based on manufacturer set price; the rebates show limited 
correlation to the degree of additional benefit so far. ConClusions: Key factors for 
positive AMNOG decisions are conducting superiority trials on mortality or at least 
morbidity/QoL against active comparators. If benefits are based on soft end-points, 
it is crucial to demonstrate these on high quality, preferably German data. Indirect 
comparisons seem to be challenged as proof of additional benefits.
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Eu PayEr anD DEcIsIon makEr usE of obsErvatIonal stuDIEs for 
HEaltH carE rEImbursEmEnt DEcIsIons
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Park, NC, USA, 3RTI Health Solutions, Manchester, UK
objeCtives: As cost-containment pressures across Europe intensify, evidentiary 
hurdles to justify new drugs will continue to grow. Data from clinical trials alone are 
no longer adequate to meet the needs of all health care decision makers (e.g., payers 
and health technology assessment [HTA] agencies, physicians and patients), driving 
a need for robust, complementary data. However, perceived need to collect real-world 
clinical, patient-centered, and/or economic outcomes through observational studies 
varies across countries, stakeholders and organizations. The objective was to better 
understand how decision makers use observational studies to inform reimburse-
ment and/or market access decisions for new products. Methods: Desktop research 
identified the types of observational studies most valuable for reimbursement deci-
sion making. This project extends a United States (US) payer study by conducting 
qualitative one-on-one interviews with decision makers across Europe to review the 
need for real-world evidence. Participants represented national and regional decision 
makers from several European countries, to identify specific evidence requirements 
and design attributes most accepted by payers/ HTA advisors and to understand 
how real-world evidence contributes to the value of a new drug from the decison-
makers’ perspectives. Results: Data from observational studies are used to describe 
patient segments, understand treatment patterns, resource utilization, and provide 
effectiveness data that supplement clinical trial data as well as inform risk sharing 
schemes. Observational studies help inform payer decision making but the valid-
ity and robustness of the results is often scrutinized. Publication of observational 
data in a Tier 1, peer-reviewed journal lends critical credibility to real-world study 
of economic development and a representative sample of medicines. Methods: 
The indices were developed using the Fisher EKS method. In order to construct 
an index the products needed to be defined as like. The definition of like in this 
study was based on molecules which are deemed to deliver equivalent health 
outcomes. This is a very broad definition and allows a large number of coun-
tries and molecules to be included in the indices. Two price indices have been 
constructed. The first compares prices of mostly off-patent medicines across 56 
countries over the period from 2005 to 2011 and included 42 molecules which 
were sold in each country for the period. The second examined on-patent medi-
cines across 17 countries and 9 molecules. Results: The results showed prices 
varied significantly between regions and that prices of genericised medicines 
both fell and converged over time. For the mostly generic drugs index the regions 
from lowest to highest price were - Region of the Americas A; South-East Asian 
Region D; South-East Asian Region B; European Region B; Western Pacific Region A; 
European Region A; African Region E; European Region C; Western Pacific Region 
B; Eastern Mediterranean Region D; Region of the Americas D; Region of the 
Americas B and Eastern Mediterranean Region B. Prices tended to be similar 
within each region. These results will be presented in detail. ConClusions: This 
research makes a unique contribution to our understanding of drug prices. It is 
the largest international comparison of pharmaceutical prices ever undertaken; 
employs new method to pharmaceutical pricing indices through the Fisher EKS 
method and outcomes based definitions of equivalence and examines genericised 
and on-patent markets separately.
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transParEncy of tHE mEDIcInEs rEImbursEmEnt systEm In IrElanD: a 
quantatIvE analysIs of tHE InfluEncEs on rEImbursEmEnt DEcIsIons 
[2006-2013]
Mahon S., Redmond S., Carney P.
GlaxoSmithKline, Dublin, Ireland
objeCtives: To identify what process and technology related characteristics influ-
ence reimbursement decisions in Ireland. Methods: Using publically available 
data compiled from the NCPE and HSE websites from 2006 to 2013, we examined sev-
eral variables (disease area; transparency; and, assessment and judgement of effect 
and CE), as defined in Fischer (2013), to identify what influences reimbursement 
decisions made through the community drugs schemes (i.e. GMS, and High Tech 
schemes). Analyses included, Spearman’s Rank Correlation (SRC), Kruskal-Wallis 
and Fishers exact tests in the univariate analyses, and a step-wise multivariate 
regression. Results: For technology features most disease areas were found not 
to have a significant influence on reimbursement decisions (SRC: max 0.30, Fishers 
Exact: p> 0.10; and, regression analysis p> 0.10). However, treatments for endocrine 
conditions were significant (p< 0.10). For process features the availability, quantity, 
and type of assessment information were strongly correlated with reimbursement 
decision (SRC: ≥ 0.73). Judgement of effect and cost-effectiveness were significant 
(p< 0.05), and the multivariate regression showed “transparency”, “judgement of 
effect” and “judgement of CE” to be statistically significant (odds ratios: 0.095, 
2.752, and 3.657 respectively; p< 0.10). ConClusions: Overall, increased trans-
parency (i.e. publically available documentation of the decision rationale) has a 
negative influence on the likelihood of reimbursement. This can be explained by 
the Rapid Review process, whereby products are initially screened and selected for 
further HTA analysis. As expected, those not selected for HTA are more likely to 
be reimbursed, but have less documentation supporting the decision, introducing 
less transparency overall. Where a HTA has been conducted, judgement of effec-
tiveness and cost-effectiveness has strong positive influence on reimbursement, 
with cost-effectiveness being the strongest positive influence. Fisher (2013) found 
stakeholder involvement to be an important influence; this could not be tested in 
the Irish context as the numbers of stakeholders known to be involved are constant 
across all observations.
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rElEvancE of a natIonal forEcast growtH ratE, as a rEgulatIon 
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objeCtives: In France, a forecast growth rate in spending related to the list of 
expensive hospital drugs, funded in addition to DRG-based payment, is determined 
annually (2% in 2012). If hospitals exceed the rate, they will be controlled, based on 
the proper use of drugs. The objective is to question the relevance of this national 
growth rate as a regulation tool. Methods: This study used 2011/2012 data from 
“medicalized information system program”. Expensive drug expenditures are 
aggregated by each type of French hospitals (without private sector): cancer cent-
ers (CC= 19), university hospitals (UH= 32), hospitals centers (HC= 415) and private 
non-profit hospitals (PNPH= 104). In order to identify their specificities, we analyzed 
the expenditures of the first therapeutic class in value by hospital type and how 
much the top 3 drugs, that drive the overall growth, contribute to their respective 
growth. Results: Overall spending grew by 4.95% in 2012. Antineoplastic drugs (1% 
of decrease) represent 48% of overall expenditures. Their market share varies from 
34% in UH expenditures to 95% in CC, the only hospital type that meet the forecast 
rate. The top 3 drugs (2 immunosuppressant drugs and 1 replacement enzyme; 
17% of overall expenditures) contribute to 3.93 points of the total growth. Their 
contribution to the growth of each hospital types is uneven: from -0.02 point out of 
-6% in CC to 5.35 points out of 9.03% in UH. ConClusions: There is a divergence 
in the growth of spending for the different hospital types because of their specific 
characteristics leading to different consumption profiles. Therefore, some hospitals 
are more impacted by changes in the spending structure, as CC for antineoplastic 
drugs. A regulation by an annual growth rate is useful because of its flexibility. But 
relevance of a single national rate does not reflect the care’s offer heterogeneity 
and needs local analyses.
